Cristália enters in the dysfunction market

Before the end of this year the Brazilian Cristália Produtos Químicos Farmacêuticos should enter into the list of the few pharmaceutical industries that dispute the billionaire market of Phosphodiesterase-5 (PDE-5) selective inhibitors, therapeutic class of the most modern drugs for sexual impotence. Cristália’s drug, Lodenafil, in advanced phase of research, has just gained an important endorsement to reach the market: the granting of the patent request in the biggest consumer market, the United States.

The company’s president, Ogari Pacheco, said that the United States patent examining body issued the "Notice of Allowance". "We passed through all the phases of the tests. Now we are with our molecule protected and we are the fourth company having an active substance in this market”. In addition to the United States, Cristália is awaiting the recognition of Lodenafil’s patent in more 44 countries, including Brazil.


Source: Gazeta Mercantil - April 6th, 06